Table 1.
Clinical characteristics | GC patients (n=77) n (%) |
Cohort 1 (n=41) n (%) |
Cohort 2 (n=36) n (%) |
P | |
---|---|---|---|---|---|
Gender | male | 53 (68.831%) | 26 (63.415%) | 27 (75.000%) | 0.273 |
female | 24 (31.169%) | 15 (36.585%) | 9 (25.000%) | ||
Age | <60 | 41 (53.247%) | 24 (58.537%) | 17 (47.222%) | 0.321 |
≥60 | 36 (46.753%) | 17 (41.463%) | 19 (52.778%) | ||
ECOG score | ≤2 | 63 (81.818%) | 34 (82.927%) | 29 (80.556%) | 0.788 |
>2 | 14 (18.182%) | 7 (17.073%) | 7 (19.444%) | ||
TNM stage | II | 22 (28.571%) | 7 (17.073%) | 15 (41.667%) | 0.017 |
III-IV | 55 (71.429%) | 34 (82.927%) | 21 (58.333%) | ||
Surgery history | Yes | 46 (59.740%) | 18 (43.902%) | 28 (77.778%) | 0.002 |
No | 31 (40.260%) | 23 (56.098%) | 8 (22.222%) | ||
Smoked | Yes | 27 (35.065%) | 15 (36.585%) | 12 (33.333%) | 0.765 |
No | 50 (64.935%) | 26 (63.415%) | 24 (66.667%) | ||
family cancer history | Yes | 14 (18.182%) | 6 (14.634%) | 8 (22.222%) | 0.389 |
No | 63 (81.818%) | 35 (85.366%) | 28 (77.778%) | ||
other chronic disease | Yes | 20 (25.974%) | 10 (24.390%) | 10 (27.778%) | 0.735 |
No | 57 (74.026%) | 31 (75.610%) | 26 (72.222%) | ||
mPFS (month) | median | 8.87 | 10.67 | 8.1 | 0.003 |
mOS (month) | median | 14.83 | 15.7 | 10.83 | 0.021 |
IL-2 | median[Q1, Q3] | 1.740[1.210,2.590] | 1.960[1.420,2.600] | 1.490[1.110,2.260] | 0.213 |
IL-4 | median[Q1, Q3] | 1.990[0.910,3.310] | 2.370[1.020,3.310] | 1.930[0.800,3.080] | 0.444 |
IL-6 | median[Q1, Q3] | 6.100[3.970,14.190] | 12.060[5.020,18.060] | 4.850[2.980,8.280] | <0.001 |
IL-10 | median[Q1, Q3] | 2.690[1.870,3.790] | 2.860[1.870,3.840] | 2.650[1.890,3.650] | 0.748 |
TNF-α | median[Q1, Q3] | 1.940[1.300,2.700] | 1.870[1.470,2.550] | 2.230[1.230,2.910] | 0.537 |
IFN-γ | median[Q1, Q3] | 2.060[1.460,2.590] | 2.110[1.500,2.560] | 1.940[1.460,2.620] | 0.736 |
IL-17A | median[Q1, Q3] | 5.680[2.900,9.260] | 5.680[2.340,9.890] | 5.720[3.190,8.910] | 0.779 |
TLC | median[Q1, Q3] | 1.320[1.040,1.700] | 1.310[1.000,1.790] | 1.370[1.200,1.690] | 0.721 |
NLR | median[Q1, Q3] | 2.338[1.571,3.444] | 2.600[1.692,4.500] | 2.338[1.571,2.628] | 0.234 |
PLR | median[Q1, Q3] | 149.231[109.924,209.375] | 149.231[109.924,205.833] | 149.693[114.557,223.171] | 0.732 |
LMR | median[Q1, Q3] | 3.478[2.370,4.238] | 3.462[2.167,4.238] | 3.714[2.726,3.953] | 0.713 |
Eastern Cooperative Oncology Group Performance Status (ECOG PS). P < 0.05 was considered statistically significant and shown in bold type.